Werner Mendling

Helios Universitätsklinikum Wuppertal

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Axel Schäfer

University of Giessen

Gerd Neumann

University of Potsdam

Udo B. Hoyme

Klinik für Frauenheilkunde

Alexander Swidsinski

Charité - Universitätsmedizin Berlin

Gilbert Donders

Antwerp University Hospital

Vera Loening‐Baucke

Charité - Universitätsmedizin Berlin

Sonja Swidsinski

Charité - Universitätsmedizin Berlin

Daniel Surbek

University Hospital of Bern

Hans Verstraelen

Ghent University Hospital

Monika Nothacker

Association of the Scientific Medical Societies

Cooperative Institutions

Charité - Universitätsmedizin Berlin

172

Walter de Gruyter (Germany)

134

Klinik für Frauenheilkunde

Ludwig-Maximilians-Universität München

Sidra Medical and Research Center

Weill Cornell Medical College in Qatar

Heidelberg University

Humboldt-Universität zu Berlin

Universitäts Frauenklinik

Cornell University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Astodrimer sodium and bacterial vaginosis: a mini review

Archives of Gynecology and Obstetrics (2022)

Werner Mendling Wolfgang Holzgreve

Abstract Bacterial vaginosis (BV) is the most common vaginal infection affecting women of childbearing age, and is associated with a substantial burden on women’s physical, emotional, sexual and social lives, as well as being linked to a number of gynaecological and obstetrical complications and adverse pregnancy outcomes. Antibiotics, such as metronidazole or clindamycin, are recommended as first-line treatment for BV, but may be associated with antibiotic resistance, high rates of recurrence and poor patient treatment satisfaction. Astodrimer sodium gel is a novel, non-antibiotic treatment for BV that is not systemically absorbed. It prevents pathogenic bacteria from adhering to the vaginal wall, and disrupts and inhibits the formation of pathogenic bacterial biofilms. Clinical cure rates of 50–57% were observed in patients with BV treated with astodrimer sodium compared with 17–21% treated with placebo ( p < 0.001) in Phase 3 trials. In a separate Phase 3 trial, recurrence of BV occurred in 44% of patients treated with astodrimer sodium compared with 54% of patients who received placebo ( p = 0.015). Astodrimer sodium is well tolerated, with vulvovaginal candidosis being the only treatment-related adverse event reported to occur more often than with placebo. The availability of astodrimer sodium, a well-tolerated, convenient, non-antibiotic treatment for BV, represents significant progress in the treatment of this burdensome condition.

10.1007/s00404-022-06429-z

Cite

Citations (10)

Masthead

Journal of Perinatal Medicine (2012)

J Dudenhausen E. Saling A Kurjak Rehovot Blickstein Neonatology Romero

10.1515/jpm-2012-masthead4

Cite

Citations (0)

Consensus on Treatment Recommendations for Urogenital Infections in Type 2 Diabetics

E. R. Weißenbacher Michael Autenrieth Bauer Hw Anne E. Becker Martin Füchtenbusch

Introduction: Diabetes involves general weakness of the immune system, posing a specialised care issue. Clinical experience has shown infection risk in the urogenital tract to be especially high with poor metabolic control compared to non-diabetics, although exact figures have yet to be reported. An expert group of diabetologists, urologists and gynaecologists carried out a survey to determine the actual frequency of urogenital infections reported in outpatient treatment of type 2 diabetes towards defining a consensus document for treatment recommendations. Methods: A questionnaire was sent to 1 194 family doctors involved in diabetes treatment from September to November 2011. Results: A hundred and twenty offices filled out and returned the questionnaires, and eighty-five were included in analysing data from 51 723 type 2 diabetic patients. Urogenital infections requiring treatment were documented in 14% of patients, 81 % of which affected the urinary tract and 16% affected the genitals; women were more often affected at 74% and 64%, respectively. 13% of the patients needed to be referred to a specialist, and the condition worsened in 3.3% of patients. Conclusions: Urogenital infections are a common complication in patients with type 2 diabetes; most infections are easy to treat with the right therapy, and do not lead to complications.

Source

Cite

Citations (0)

[Some new aspects of vaginal candidosis in the female].

PubMed (1992)

Werner Mendling

Vaginal infections

Source

Cite

Citations (0)

S1-Guideline on Bacterial Vaginosis in Gynecology and Obstetrics

Geburtshilfe und Frauenheilkunde (2014)

Werner Mendling J. Martius Udo B. Hoyme

Normal vaginal flora of sexually mature women consists of lactobacilli, transient or commensal anaerobic and aerobic bacteria, and Candida species from skin and gut flora. The normal pH value of vaginal flora is 3.8–4.4. Lactobacilli predominate in the vaginal flora, primarily L. crispatus, L. gasseri, L. iners and L. jensenii, depending on ethnicity. Normal pH values differ significantly between ethnicities, ranging from 3.8 to 5.2. Some healthy women have no lactobacilli in their vaginal flora; the percentage of women with lactobacilli differs depending on ethnicity; the percentage for Caucasian women is around 9 %, for Hispanic and African women the percentage is more than 30 % with normal pH values of around 5 [14], [43]. At present, there are no studies into this issue for Europe.

Vaginal flora

Flora

10.1055/s-0033-1360230

Cite

Citations (13)

Adnexitis

Springer eBooks (2014)

Gerd Neumann Axel Schäfer Werner Mendling

10.1007/978-3-642-38310-6_19

Cite

Citations (0)

Prävention und Therapie der Frühgeburt. Leitlinie der DGGG, OEGGG und SGGG (S2k-Niveau, AWMF-Registernummer 015/025, Februar 2019) – Teil 2 mit Empfehlungen zur tertiären Prävention der Frühgeburt und zum Management des frühen vorzeitigen Blasensprungs

Zeitschrift für Geburtshilfe und Neonatologie (2019)

Richard E. Berger Harald Abele Franz Bahlmann Ivonne Bedei Klaus Doubek

This is an official guideline of the German Society for Gynecology and Obstetrics (DGGG), the Austrian Society for Gynecology and Obstetrics (ÖGGG) and the Swiss Society for Gynecology and Obstetrics (SGGG). The aim of this guideline is to improve the prediction, prevention and management of preterm birth based on evidence obtained from recently published scientific literature, the experience of the members of the guideline commission and the views of self-help groups.The members of the participating medical societies and organizations developed Recommendations and Statements based on the international literature. The Recommendations and Statements were adopted following a formal consensus process (structured consensus conference with neutral moderation, voting done in writing using the Delphi method to achieve consensus).Part 2 of this short version of the guideline presents Statements and Recommendations on the tertiary prevention of preterm birth and the management of preterm premature rupture of membranes.ZIEL: Offizielle Leitlinie der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG), der Österreichischen Gesellschaft für Gynäkologie und Geburtshilfe (ÖGGG) und der Schweizerischen Gesellschaft für Gynäkologie und Geburtshilfe (SGGG). Ziel der Leitlinie ist es, die Prädiktion, die Prävention und das Management der Frühgeburt anhand der aktuellen Literatur, der Erfahrung der Mitglieder der Leitlinienkommission einschließlich der Sicht der Selbsthilfe evidenzbasiert zu verbessern. METHODEN: Anhand der internationalen Literatur entwickelten die Mitglieder der beteiligten Fachgesellschaften und Organisationen Empfehlungen und Statements. Diese wurden in einem formalen Prozess (strukturierte Konsensuskonferenzen mit neutraler Moderation, schriftliche Delphi-Abstimmung) verabschiedet. EMPFEHLUNGEN: Der Teil 2 dieser Kurzversion der Leitlinie zeigt Statements und Empfehlungen zur tertiären Prävention der Frühgeburt sowie zum Management des frühen vorzeitigen Blasensprungs.

10.1055/a-1008-8730

Cite

Citations (13)

EuroGuiderm guideline on lichen sclerosus—Treatment of lichen sclerosus

Journal of the European Academy of Dermatology and Venereology (2024)

Gudula Kirtschig Maria Kinberger Alexander Kreuter Rosalind Simpson Andreas R. Günthert

Lichen sclerosus (LS) is an inflammatory skin disease affecting all ages. LS typically involves the anogenital site where it causes itching and soreness; it may lead to sexual and urinary dysfunction in females and males; however, it may be asymptomatic. First signs of LS are usually a whitening of the genital skin, sometimes preceded by redness and oedema; fissuring, scarring, shrinkage and fusion of structures may follow in its course. LS is associated with an increased risk of genital cancer. LS has a huge impact on the quality of life of affected patients, and it is important to raise more awareness of this not uncommon disease in order to diagnose and treat it early.

Guideline

10.1111/jdv.20083

Cite

Citations (8)

Harnwegsinfektionen

Springer eBooks (2014)

Gerd Neumann Axel Schäfer Werner Mendling

10.1007/978-3-642-38310-6_20

Cite

Citations (0)

Sexuell übertragbare Infektionen bei der jungen Patientin

Die Gynäkologie (2023)

Kristina Wihlfahrt Anna Westermann Nicolaì Maass Werner Mendling İbrahim Alkatout

10.1007/s00129-023-05059-z

Cite

Citations (0)